Abstract

BackgroundAdoptive transfer of minor histocompatibility antigen (MiHA)-specific T cells is a promising therapy for patients with hematological cancers. However, the efficacy of the transferred cells is hampered by the acquisition of terminal effector differentiation and exhaustion features during expansion in vitro thus preventing their function and persistence in vivo. Yet, the factors that induce T-cell differentiation and functional impairment in culture remain poorly defined and are likely to vary depending on the method used for expansion.MethodsUsing the clinically relevant HLA-A0201-restricted MiHA HA-1 as well as reagents and procedures that are readily transferable to a clinical environment, we designed a novel culture protocol and defined how exhaustion features appeared in function of time. The optimal time points for the expansion of “fit” MiHA-specific T cells were delineated using phenotypic and functional assessments including KLRG-1 and PD-1 surface markers as well as Ki67 staining and cytokine secretion assays.ResultsFollowing a priming phase, an enrichment step and a rapid expansion stage, our method generates MiHA-specific T-cell lines. Evidence of phenotypic and functional dysfunction appear in function of culture duration, but display different characteristics following the extension of the priming or rapid expansion phases. While repeated antigen exposure during the priming phase induced the decline of the antigen-specific population and the expression of PD-1 and KLRG-1 on antigen-specific CD8+ T cells, the prolongation of an antigen-free expansion phase induced proliferation arrest and the relative loss of antigen-specific cells without impairing polyfunctional cytokine secretion or inducing PD-1 and KLRG-1 expression. A similar pattern was also observed after stimulating a virus-specific memory repertoire, except for the more rapid acquisition of exhaustion features upon repeated antigen exposure.ConclusionOur results offer novel insights on the impact of culture duration on the acquisition of T-cell exhaustion features. Using a new clinical-compliant protocol, we define critical parameters to monitor in order to optimally differentiate and expand MiHA-specific T cells in culture prior to adoptive transfer.Electronic supplementary materialThe online version of this article (doi:10.1186/s12967-015-0495-z) contains supplementary material, which is available to authorized users.

Highlights

  • Adoptive transfer of minor histocompatibility antigen (MiHA)-specific T cells is a promising therapy for patients with hematological cancers

  • Antigen-presenting cells efficiently prime MiHA-specific T cells in G-Rex bioreactors Based on established methods [1,8,15,16,17], we assessed the effect of repetitive weekly stimulation on the priming and expansion of MiHA-specific CD8+ T cells

  • Exogenous cytokines were introduced at different stages of the culture (IL-12 and IL-21 the first week; IL-21, IL-2, IL-7 and IL-15 the second week and IL-2, IL-7 and IL-15 for the subsequent weeks) to promote T cell differentiation, survival and expansion [19,20,21,22,23]

Read more

Summary

Introduction

Adoptive transfer of minor histocompatibility antigen (MiHA)-specific T cells is a promising therapy for patients with hematological cancers. MiHAs are naturally processed peptides from polymorphic endogenous proteins that are loaded onto HLA molecules and presented at the cell surface [4]. At this time, MiHA-based immunotherapy in the setting of HSCT is one of the most potent forms of cancer treatment, but it remains nonspecific and can lead to widespread anti-host alloreactivity in the form of Graft-versus-host disease (GVHD) [5]. The differentiation, expansion, and adoptive transfer of hematopoietic-restricted MiHA-specific T cells is an attractive approach to augment the GVL effects without risking GVHD [6,7]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call